Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors

Vaccine

Volumn 24, Issue 3, 2006, Pages 304-316

  Helguera, Gustavo ^a   Dela Cruz, Jay S ^a   Lowe, Christine ^a   Ng, Patrick P ^a   Trinh, Ryan ^a   Morrison, Sherie L ^a   Penichet, Manuel L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody fusion proteins; Cytokines; Immunotherapy

Indexed keywords

ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IMMUNOGLOBULIN G3; INTERLEUKIN 12; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; CANCER IMMUNIZATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN FUNCTION; RAT; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SPACE; GENES, ERBB-2; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN-12; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; NEOPLASMS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; VACCINATION;

EID: 29044436020     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.07.073     Document Type: Article

References (55)

1. R. Roskoski Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem Biophys Res Commun 319 1 2004 1 11
2. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 6835 2001 355 365
3. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 1987 177 182
4. D.F. Hayes, H. Yamauchi, G. Broadwater, C.T. Cirrincione, S.P. Rodrigue, and D.A. Berry Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662 Clin Cancer Res 7 9 2001 2703 2711
5. A. Stark, B.S. Hulka, S. Joens, D. Novotny, A.D. Thor, and L.E. Wold HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer J Clin Oncol 18 2 2000 267 274
6. P. Carter, L. Presta, C.M. Gorman, J.B. Ridgway, D. Henner, and W.L. Wong Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 10 1992 4285 4289
7. C.L. Vogel, M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, and L. Fehrenbacher First-line Herceptin monotherapy in metastatic breast cancer Oncology 61 Suppl. 2 2001 37 42
8. E.A. Grimm, and L. Owen-Schaub The IL-2 mediated amplification of cellular cytotoxicity J Cell Biochem 45 4 1991 335 339
9. I. Yron, T. Wood Jr., P.J. Spiess, and S.A. Rosenberg In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors J Immunol 125 1 1980 238 245
10. L.T. Bich-Thuy, M. Dukovich, N.J. Peffer, A.S. Fauci, J.H. Kehrl, and W.C. Greene Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein J Immunol 139 5 1987 1550 1556
11. K.M. Heaton, G. Ju, D.K. Morris, K. Delisio, P. Bailon, and E.A. Grimm Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor Cell Immunol 147 1 1993 167 179
12. K. Tsung, J.B. Meko, G.R. Peplinski, Y.L. Tsung, and J.A. Norton IL-12 induces T helper 1-directed antitumor response J Immunol 158 7 1997 3359 3365
13. P. Puddu, L. Fantuzzi, P. Borghi, B. Varano, G. Rainaldi, and E. Guillemard IL-12 induces IFN-gamma expression and secretion in mouse peritoneal macrophages J Immunol 159 7 1997 3490 3497
14. J. Chehimi, S.E. Starr, I. Frank, M. Rengaraju, S.J. Jackson, and C. Llanes Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients J Exp Med 175 3 1992 789 796
15. M.S. Gee, C.J. Koch, S.M. Evans, W.T. Jenkins, C.H. Pletcher Jr., and J.S. Moore Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12 Cancer Res 59 19 1999 4882 4889
16. C. Ruef, and D.L. Coleman Granulocyte-macrophage colony-stimulating factor: pleiotropic cytokine with potential clinical usefulness Rev Infect Dis 12 1 1990 41 62
17. R. Soiffer, T. Lynch, M. Mihm, K. Jung, C. Rhuda, and J.C. Schmollinger Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma Proc Natl Acad Sci USA 95 22 1998 13141 13146
18. G. Dranoff, E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, and K. Brose Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 90 8 1993 3539 3543
19. C.L. Addison, J.L. Bramson, M.M. Hitt, W.J. Muller, J. Gauldie, and F.L. Graham Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors Gene Ther 5 10 1998 1400 1409
20. H.N. Lode, R. Xiang, S.R. Duncan, A.N. Theofilopoulos, S.D. Gillies, and R.A. Reisfeld Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12 Proc Natl Acad Sci USA 96 15 1999 8591 8596
21. M. Vagliani, M. Rodolfo, F. Cavallo, M. Parenza, C. Melani, and G. Parmiani Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells Cancer Res 56 3 1996 467 470
22. T. Kikuchi, T. Joki, S. Saitoh, Y. Hata, T. Abe, and N. Kato Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system Int J Cancer 80 3 1999 425 430
23. J.M. Wigginton, K.L. Komschlies, T.C. Back, J.L. Franco, M.J. Brunda, and R.H. Wiltrout Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma J Natl Cancer Inst 88 1 1996 38 43
24. J.A. Berzofsky, J.D. Ahlers, and I.M. Belyakov Strategies for designing and optimizing new generation vaccines Nat Rev Immunol 1 3 2001 209 219
25. A. Aruga, K. Tanigawa, E. Aruga, H. Yu, and A.E. Chang Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity Cancer Gene Ther 6 1 1999 89 95
26. H.C. Hill, T.F. Conway Jr., M.S. Sabel, Y.S. Jong, E. Mathiowitz, and R.B. Bankert Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease Cancer Res 62 24 2002 7254 7263
27. Z. Wang, S.J. Qiu, S.L. Ye, Z.Y. Tang, and X. Xiao Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma Cancer Gene Ther 8 10 2001 751 758
28. M.L. Penichet, J.S. Dela Cruz, S.U. Shin, and S.L. Morrison A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors Hum Antibodies 10 1 2001 43 49
29. L.S. Peng, M.L. Penichet, and S.L. Morrison A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity J Immunol 163 1 1999 250 258
30. J.S. Dela Cruz, K.R. Trinh, S.L. Morrison, and M.L. Penichet Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity J Immunol 165 9 2000 5112 5121
31. J.S. Dela Cruz, S.Y. Lau, E.M. Ramirez, C. De Giovanni, G. Forni, and S.L. Morrison Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice Vaccine 21 13-14 2003 1317 1326
32. S. Rovero, A. Amici, E.D. Carlo, R. Bei, P. Nanni, and E. Quaglino DNA vaccination against rat her-2/Neu pl85 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice J Immunol 165 9 2000 5133 5142
33. D.S. Schoenhaut, A.O. Chua, A.G. Wolitzky, P.M. Quinn, C.M. Dwyer, and W. McComas Cloning and expression of murine IL-12 J Immunol 148 11 1992 3433 3440
34. G. Helguera, and M.L. Penichet Adoptive immunotherapy: methods and protocols Antibody-cytokine fusion proteins for the therapy of cancer 2005 Humana Press Totowa, NJ p. 347-73
35. S.U. Shin, and S.L. Morrison Production and properties of chimeric antibody molecules Methods Enzymol 178 1989 459 476
36. E. Harlow, and D. Lane Antibodies: a laboratory manual Anti-immunoglobulin antibodies 1989 Cold Spring Harbor Laboratory New York p. 623-31
37. P.M. Challita-Eid, M.L. Penichet, S.U. Shin, T. Poles, N. Mosammaparast, and K. Mahmood A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway J Immunol 160 7 1998 3419 3426
38. E.T. Harvill, and S.L. Morrison An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL2-R Immunotechnology 1 1995 95 105
39. G. Carlsson, L. Ekelund, L. Stigsson, and L. Hafstrom Vascularization and tumour volume estimations of solitary liver tumours in rats Ann Chir Gynaecol 72 4 1983 187 191
40. M.L. Penichet, S.U. Shin, and S.L. Morrison Fab fusion proteins: immunoligands S.M. Chamow A. Ashkenazi Antibody fusion proteins 1999 John Wiley & Son Inc. New York p. 15-52
41. G.J. Lieschke, P.K. Rao, M.K. Gately, and R.C. Mulligan Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo Nat Biotechnol 15 1 1997 35 40
42. R.J. Robb, R.M. Kutny, M. Panico, H.R. Morris, and V. Chowdhry Amino acid sequence and post-translational modification of human interleukin 2 Proc Natl Acad Sci USA 81 20 1984 6486 6490
43. M.K. Gately, R.R. Warder, S. Honasoge, D.M. Carvajal, D.A. Faherty, and S.E. Connaughton Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo Int Immunol 6 1 1994 157 167
44. J.L. Dangl, T.G. Wensel, S.L. Morrison, L. Stryer, L.A. Herzenberg, and V.T. Oi Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies EMBO J 7 7 1988 1989 1994
45. M.L. Phillips, M.H. Tao, S.L. Morrison, and V.N. Schumaker Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization Mol Immunol 31 15 1994 1201 1210
46. C.A. Janeway, P. Travers, M. Walport, and M. Schlomchick Immunobiology: the immune system in health and disease 2001 Garland Publishing New York p. 125-54
47. M.H. Tao, and S.L. Morrison Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region J Immunol 143 8 1989 2595 2601
48. I.M. Roitt J. Brostoff K. Male Immunology, 2nd ed. 1989 Gower Medical Publishing London 5.7 5.8
49. S.D. Gillies, Y. Lan, B. Brunkhorst, W.K. Wong, Y. Li, and K.M. Lo Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer Cancer Immunol Immunother 51 8 2002 449 460
50. C. Halin, V. Gafner, M.E. Villani, L. Borsi, A. Berndt, and H. Kosmehl Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha Cancer Res 63 12 2003 3202 3210
51. T.L. Stevens, A. Bossie, V.M. Sanders, R. Fernandez-Botran, R.L. Coffman, and T.R. Mosmann Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells Nature 334 6179 1988 255 258
52. R. Manetti, P. Parronchi, M.G. Giudizi, M.P. Piccinni, E. Maggi, and G. Trinchieri Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Thl)-specific immune responses and inhibits the development of IL-4-producing Th cells J Exp Med 177 4 1993 1199 1204
53. Y. Nagata, R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, and K. Furukawa Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts J Immunol 159 3 1997 1336 1343
54. C. Curcio, E. Di Carlo, R. Clynes, M.J. Smyth, K. Boggio, and E. Quaglino Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas J Clin Invest 111 8 2003 1161 1170
55. T. Yamamoto, S. Ikawa, T. Akiyama, K. Semba, N. Nomura, and N. Miyajima Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor Nature 319 6050 1986 230 234